samedan logo
 
 
spacer
home > ict > autumn 2017 > fastening pharmaceuticals
PUBLICATIONS
International Clinical Trials

Fastening Pharmaceuticals

As consumers increasingly embrace the more affordable nature of wearable devices – choosing to monitor their own health and wellbeing with gadgets such as FitBit or Jawbone – it is no surprise that the wearable device market is set to grow to £25 billion by 2019 (1). However, this wearable technology has also been widely adopted by other markets, and none more so than by the healthcare industry, which reportedly earned revenues of $5.1 billion in 2015, according to a recent report by Frost and Sullivan (2). This wearable devices market is set to continue to revolutionise the healthcare industry with estimates that it will reach over $18 billion by 2020 (3).

It has been widely reported that CROs can leverage this wearable device trend to enable easier remote patient monitoring, improved therapeutic outcomes and deeper insight into clinical studies. Alongside this, traditional outsourcing in the area of clinical trial data management is seeing notable increases in market concentration, while speciality service providers are experiencing unprecedented growth. The Tufts Center for the Study of Drug Development estimates that, since 2011, small niche or speciality service providers have enjoyed strong relative annual growth, approaching 10% (4).

However, the clinical trial process is known to be complex, painstaking and is often criticised for not being sufficiently patient-centric. Therefore, it makes sense to innovate in this area to ease the challenges, streamline the various activities and generate better patient engagement. One way to do this is via digital technology and mobile health (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jeremy Wheeler, Head of Statistics at Quanticate, is an experienced statistician with over 25 years' experience, including over 10 years in the pharma industry. He has worked in all phases of drug development, with particular knowledge of clinical studies, early phase design and analysis, methodology/biomarker studies and pharmacogenomics. Jeremy has a strong background in epidemiology and observational studies. He has applied this knowledge to post-marketing studies, meta-analyses and clinical registry studies.
spacer
Jeremy Wheeler
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Prometic Bioseparations are very pleased to introduce their new purpose built ecommerce platform (Webshop)!

Their goal was to build a platform that is easy to navigate, informative and one that makes their products and services easily accessible to researchers and laboratories worldwide. They also wanted to make ordering as quick and easy as possible to meet the needs of the rapidly progressive industry. They have reflected these requirements with an ecommerce store in order to supply high quality products to customers from academia to big pharma.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement